Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 156

Cited In for PubMed (Select 1549180)

1.

Pachymic Acid Inhibits Growth and Induces Apoptosis of Pancreatic Cancer In Vitro and In Vivo by Targeting ER Stress.

Cheng S, Swanson K, Eliaz I, McClintick JN, Sandusky GE, Sliva D.

PLoS One. 2015 Apr 27;10(4):e0122270. doi: 10.1371/journal.pone.0122270. eCollection 2015.

2.

ATM prevents DSB formation by coordinating SSB repair and cell cycle progression.

Khoronenkova SV, Dianov GL.

Proc Natl Acad Sci U S A. 2015 Mar 31;112(13):3997-4002. doi: 10.1073/pnas.1416031112. Epub 2015 Mar 16.

3.
4.

Suppressors of cytokine signaling 1 and 3 are upregulated in brain resident cells in response to virus-induced inflammation of the central nervous system via at least two distinctive pathways.

Steffensen MA, Fenger C, Christensen JE, Jørgensen CK, Bassi MR, Christensen JP, Finsen B, Thomsen AR.

J Virol. 2014 Dec;88(24):14090-104. doi: 10.1128/JVI.01346-14. Epub 2014 Sep 24.

PMID:
25253351
5.

Effect of nanostructured TiO₂ crystal phase on photoinduced apoptosis of breast cancer epithelial cells.

Lagopati N, Tsilibary EP, Falaras P, Papazafiri P, Pavlatou EA, Kotsopoulou E, Kitsiou P.

Int J Nanomedicine. 2014 Jul 3;9:3219-30. doi: 10.2147/IJN.S62972. eCollection 2014.

6.

Strategies for the Use of Poly(adenosine diphosphate ribose) Polymerase (PARP) Inhibitors in Cancer Therapy.

Ström CE, Helleday T.

Biomolecules. 2012 Dec 14;2(4):635-49. doi: 10.3390/biom2040635.

7.

Transcriptional roles of PARP1 in cancer.

Schiewer MJ, Knudsen KE.

Mol Cancer Res. 2014 Aug;12(8):1069-80. doi: 10.1158/1541-7786.MCR-13-0672. Epub 2014 Jun 10. Review.

PMID:
24916104
8.

Poly(ADP-ribose) polymerase inhibitors sensitize cancer cells to death receptor-mediated apoptosis by enhancing death receptor expression.

Meng XW, Koh BD, Zhang JS, Flatten KS, Schneider PA, Billadeau DD, Hess AD, Smith BD, Karp JE, Kaufmann SH.

J Biol Chem. 2014 Jul 25;289(30):20543-58.

PMID:
24895135
9.

Knockout of PARG110 confers resistance to cGMP-induced toxicity in mammalian photoreceptors.

Sahaboglu A, Tanimoto N, Bolz S, Garrido MG, Ueffing M, Seeliger MW, Löwenheim H, Ekström P, Paquet-Durand F.

Cell Death Dis. 2014 May 22;5:e1234. doi: 10.1038/cddis.2014.208.

10.

Suicidal cross-linking of PARP-1 to AP site intermediates in cells undergoing base excision repair.

Prasad R, Horton JK, Chastain PD 2nd, Gassman NR, Freudenthal BD, Hou EW, Wilson SH.

Nucleic Acids Res. 2014 Jun;42(10):6337-51. doi: 10.1093/nar/gku288. Epub 2014 Apr 25.

11.

Rationale for poly(ADP-ribose) polymerase (PARP) inhibitors in combination therapy with camptothecins or temozolomide based on PARP trapping versus catalytic inhibition.

Murai J, Zhang Y, Morris J, Ji J, Takeda S, Doroshow JH, Pommier Y.

J Pharmacol Exp Ther. 2014 Jun;349(3):408-16. doi: 10.1124/jpet.113.210146. Epub 2014 Mar 20.

12.

Anti-tumor activity of olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, in cultured endometrial carcinoma cells.

Miyasaka A, Oda K, Ikeda Y, Wada-Hiraike O, Kashiyama T, Enomoto A, Hosoya N, Koso T, Fukuda T, Inaba K, Sone K, Uehara Y, Kurikawa R, Nagasaka K, Matsumoto Y, Arimoto T, Nakagawa S, Kuramoto H, Miyagawa K, Yano T, Kawana K, Osuga Y, Fujii T.

BMC Cancer. 2014 Mar 13;14:179. doi: 10.1186/1471-2407-14-179.

13.

Conformational activation of poly(ADP-ribose) polymerase-1 upon DNA binding revealed by small-angle X-ray scattering.

Mansoorabadi SO, Wu M, Tao Z, Gao P, Pingali SV, Guo L, Liu HW.

Biochemistry. 2014 Mar 25;53(11):1779-88. doi: 10.1021/bi401439n. Epub 2014 Mar 11.

14.

BRCA 1/2-Mutation Related and Sporadic Breast and Ovarian Cancers: More Alike than Different.

Burgess M, Puhalla S.

Front Oncol. 2014 Feb 27;4:19. doi: 10.3389/fonc.2014.00019. eCollection 2014. Review.

15.

Antibacterial activity of a cardanol from Thai Apis mellifera propolis.

Boonsai P, Phuwapraisirisan P, Chanchao C.

Int J Med Sci. 2014 Feb 7;11(4):327-36. doi: 10.7150/ijms.7373. eCollection 2014.

16.

Tumour cell retention of rucaparib, sustained PARP inhibition and efficacy of weekly as well as daily schedules.

Murray J, Thomas H, Berry P, Kyle S, Patterson M, Jones C, Los G, Hostomsky Z, Plummer ER, Boddy AV, Curtin NJ.

Br J Cancer. 2014 Apr 15;110(8):1977-84. doi: 10.1038/bjc.2014.91. Epub 2014 Feb 20.

17.

Minor grove binding ligands disrupt PARP-1 activation pathways.

Kirsanov KI, Kotova E, Makhov P, Golovine K, Lesovaya EA, Kolenko VM, Yakubovskaya MG, Tulin AV.

Oncotarget. 2014 Jan 30;5(2):428-37.

18.

Crystallographic and biochemical analysis of the mouse poly(ADP-ribose) glycohydrolase.

Wang Z, Gagné JP, Poirier GG, Xu W.

PLoS One. 2014 Jan 21;9(1):e86010. doi: 10.1371/journal.pone.0086010. eCollection 2014.

19.

Characterization of H460R, a Radioresistant Human Lung Cancer Cell Line, and Involvement of Syntrophin Beta 2 (SNTB2) in Radioresistance.

Im CN, Kim BM, Moon EY, Hong DW, Park JW, Hong SH.

Genomics Inform. 2013 Dec;11(4):245-53. doi: 10.5808/GI.2013.11.4.245. Epub 2013 Dec 31.

20.

Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib.

Murai J, Huang SY, Renaud A, Zhang Y, Ji J, Takeda S, Morris J, Teicher B, Doroshow JH, Pommier Y.

Mol Cancer Ther. 2014 Feb;13(2):433-43. doi: 10.1158/1535-7163.MCT-13-0803. Epub 2013 Dec 19.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk